Replicel (TrichoScience) Trials Started

» » I’ve got a strange “good feeling” about this. Maybe that’s just because
» I
» » want to hope though. One thing I like is that they are not promising a
» » full head of hair, I get the feeling they are expecting around 50% or
» maybe
» » more if caught in the early stages.
» »
» » One thing I really like is that in interviews they have said they will
» go
» » to market if they can regrow more than 20% because that would make them
» the
» » new industry standard. So even if it doesn’t work as good as well all
» hope
» » but it does manage to give you 20% of your hair back… that’s a
» » life-changing win for a lot of us!!!
» »
» » I currently have 50% of my hair and since starting Propecia a few years
» ago
» » I haven’t regrown any, but I haven’t lost any. If I can hold my 50%
» with
» » propecia and get 20% more with this!!! I’m now at around 70%… then I’m
» a
» » few hair transplants away from being pretty damn close to 100%.
»
» Hey suicidal, relax. You’re instincts may be very well right. Did you know
» that stress makes your hair fall out

I’m not saying it’s 100% going to work. I’m just saying based on all the possible cures, this one seems the most promising. We will know in 4 months when they post the results of their phase 1 trials.

Not quite directly relavant but Matt Wayrynen who resigned from Replicel a lil while ago has now joined a junior gold mining company in Canada as its President. This guy is all over the map from the hair industry to the gold industry.

I guess he must be a real mover & shaker when it comes to getting financing, getting the company up & running and then jumping to the venture.


Encore Renaissance Resources Corp. Announces Appointment of New President and CEO

VANCOUVER, BRITISH COLUMBIA–(Marketwire - Oct. 13, 2011) - ENCORE RENAISSANCE RESOURCES CORP. (TSX VENTURE:EZ - News; FRANKFURT:OUH1 - News; PINK SHEETS:ERRCF - News) Encore Renaissance Resources Corp. (the “Company”) is pleased to announce the appointment of Mr. Matt Wayrynen as President and Chief Executive Officer. Mr. Wayrynen has extensive experience in resource company management, venture capital financing, and mergers and acquisitions.

Mr. Wayrynen is a former director of Quinto Mining Corporation, which was acquired by Consolidated Thompson Iron Mines in 2008 for a share value equal to $175M. He is an original co-founder and former President and Chief Executive Officer of TrichoScience Innovations Inc., which was acquired by Replicel Life Sciences Inc., and helped advance the company to its current market capitalization of over $100M. Mr. Wayrynen is currently a director and senior officer of several other reporting issuers in the resource and energy sectors. Mr. Wayrynen is also the former President and Chief Executive Officer of Bralorne Gold Mines Ltd. The Bralorne mines are located in southern British Columbia in the Lillooet Mining Division with historic gold production totaling 4.15 million ounces of gold from 52 separate veins which, at current prices, would hold a value exceeding $5B.

“I am quite prepared and up for the challenge of leading Encore forward. I am pleased to have joined the management team of EZ. Having recently completed a site visit of the property, I am excited about its potential development into a revenue-producing asset.”

The Board would also like to thank Mr. Michael Mulberry for his contributions in advancing the Company, and wish him well in his future endeavors.

This release contains statements that are forward-looking statements and are subject to various risks and uncertainties concerning the specific factors disclosed under the heading “Risk Factors” and elsewhere in the Company’s periodic filings with Canadian securities regulators. Such information contained herein represents management’s best judgment as of the date hereof based on information currently available. The Company does not assume the obligation to update any forward-looking statement.

The TSX Venture Exchange has not reviewed and does not accept the responsibility for the accuracy or adequacy of this release.